These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18778121)

  • 1. Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
    Hair PI; Keating GM; McKeage K
    Drugs; 2008; 68(14):2001-9. PubMed ID: 18778121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
    Hoy SM; Keating GM
    Drugs; 2008; 68(12):1711-21. PubMed ID: 18681493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
    Miyazaki T; Hanaoka K; Namiki A; Ogawa S; Kitajima T; Hosokawa T; Ishida T; Nogami S; Mashimo S
    Clin Drug Investig; 2008; 28(5):313-25. PubMed ID: 18407717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.
    Kress HG; Boss H; Delvin T; Lahu G; Lophaven S; Marx M; Skorjanec S; Wagner T
    Eur J Pharm Biopharm; 2010 Jun; 75(2):225-31. PubMed ID: 20152899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
    Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
    J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
    Muijsers RB; Wagstaff AJ
    Drugs; 2001; 61(15):2289-307. PubMed ID: 11772140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
    J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
    Collins JJ; Dunkel IJ; Gupta SK; Inturrisi CE; Lapin J; Palmer LN; Weinstein SM; Portenoy RK
    J Pediatr; 1999 Mar; 134(3):319-23. PubMed ID: 10064669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.
    Jeal W; Benfield P
    Drugs; 1997 Jan; 53(1):109-38. PubMed ID: 9010652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
    Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
    Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
    Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
    Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.
    Vielvoye-Kerkmeer AP; Mattern C; Uitendaal MP
    J Pain Symptom Manage; 2000 Mar; 19(3):185-92. PubMed ID: 10760623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.
    Mystakidou K; Befon S; Tsilika E; Dardoufas K; Georgaki S; Vlahos L
    Oncology; 2002; 62(1):9-16. PubMed ID: 11810038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of cancer-related pain with transdermal fentanyl.
    Leelanuntakit S
    J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
    Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
    Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects.
    Marier JF; Lor M; Potvin D; Dimarco M; Morelli G; Saedder EA
    J Clin Pharmacol; 2006 Jun; 46(6):642-53. PubMed ID: 16707411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.